Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8665717 | 0.85 | AKR1B1 (0.38) | KEAP1HTTMAPTPOLBTDP1 | |
| SCHEMBL294572 | 0.78 | MAOA (0.41) | MAOAMAOB | |
| SCHEMBL7977979 | 0.78 | MAOA (0.43) | MAOAMAOB | |
| SCHEMBL511051 | 0.75 | MAOA (0.38) | MAOAMAOB | |
| SCHEMBL293444 | 0.74 | MAOA (0.37) | MAOAMAOB | |
| SCHEMBL4530544 | 0.74 | MAOA (0.37) | HTTALDH1A1MAOAMAOBCYP1A2 | |
| SCHEMBL295033 | 0.74 | MAOA (0.43) | MAOAMAOB | |
| SCHEMBL295082 | 0.73 | MAOA (0.36) | MAOAMAOB | |
| SCHEMBL16397646 | 0.73 | MAOA (0.42) | HTTALDH1A1HSD17B10MAOAMAOB | |
| SCHEMBL212723 | 0.73 | MAOA (0.42) | HTTALDH1A1HSD17B10MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161261-B1 | Materials and methods for treating coagulation disorders | ARMETHEON INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-7932405-B2 | Halogenated ester derivatives of coumarins for the treatment of coagulation disorders | ARYX THERAPEUTICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2161261-A1 | Materials and methods for treating coagulation disorders | Aryx Therapeutics (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7666902-B2 | 1,1,1,3,3,3-hexachloro-2-methylpropan-2-yl 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)benzoate; side effect reduction over warfarin | ARYX THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090082430-A1 | Materials and Methods for Treating Coagulation Disorders | ARYX THERAPEUTICS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | DRUZGALA PASCAL | 2008-09-11 | — | — | US | disclosed |
| US-20080027132-A1 | Materials and Methods For Treating Coagulation Disorders | ARYX THERAPEUTICS (US) | 2008-01-31 | — | — | US | disclosed |
| US-7285671-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2007-10-23 | — | — | US | disclosed |
| US-7253208-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070129429-A1 | Materials And Methods For Treating Coagulation Disorders | ARYX THERAPEUTICS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20060287388-A1 | Materials and Methods for Treating Coagulation Disorders | ARYX THERAPEUTICS (US) | 2006-12-21 | — | — | US | disclosed |
| US-7145020-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050245603-A1 | Materials and methods for treating coagulation disorders | ESPERO BIOPHARMA, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005100336-A1 | MATERIALS AND METHODS FOR TREATING COAGULATION DISORDERS | ARYX THERAPEUTICS (US) | 2005-10-27 | — | — | WO | disclosed |
| US-6864279-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040220258-A1 | Materials and methods for treating coagulation disorders | ESPERO BIOPHARMA, INC. | 2004-11-04 | — | — | US | disclosed |
| CN-1520324-A | Antiangiogenic combination thereapy for treatment of cancer | — | 2004-08-11 | — | — | CN | disclosed |
| EP-1383756-A1 | COUMARIN DERIVATIVES TO BE USED AS ANTICOAGULANTS | Arxy Therapeutics (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030199573-A1 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2002085882-A1 | COUMARIN DERIVATIVES TO BE USED AS ANTICOAGULANTS | ARXY THERAPEUTICS (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245603-A1 | Materials and methods for treating coagulation disorders | F12, F2, SERPINC1 | KEAP1 565/4885FFAR1 4049/4885HTT 3077/4885 |
| US-20030199573-A1 | Materials and methods for treating coagulation disorders | CES1, F2, CYP3A5 | KEAP1 418/4885FFAR1 3421/4885HTT 2924/4885 |
| US-20060287388-A1 | Materials and Methods for Treating Coagulation Disorders | F12, F2, SERPINC1 | KEAP1 565/4885FFAR1 4049/4885HTT 3077/4885 |
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | CES1, F2, CYP3A5 | KEAP1 418/4885FFAR1 3421/4885HTT 2924/4885 |
| US-20080027132-A1 | Materials and Methods For Treating Coagulation Disorders | F12, F2, SERPINC1 | KEAP1 565/4885FFAR1 4049/4885HTT 3077/4885 |
| US-20090082430-A1 | Materials and Methods for Treating Coagulation Disorders | F12, F2, SERPINC1 | KEAP1 565/4885FFAR1 4049/4885HTT 3077/4885 |
| US-20070129429-A1 | Materials And Methods For Treating Coagulation Disorders | CES1, F2, CYP3A5 | KEAP1 418/4885FFAR1 3421/4885HTT 2924/4885 |
| US-20040220258-A1 | Materials and methods for treating coagulation disorders | CES1, F2, CYP3A5 | KEAP1 418/4885FFAR1 3421/4885HTT 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.